Fagron NV
XBRU:FAGR
Intrinsic Value
Fagron NV engages in the development, marketing, and distribution of healthcare products and services. [ Read More ]
The intrinsic value of one FAGR stock under the Base Case scenario is 24.44 EUR. Compared to the current market price of 18.76 EUR, Fagron NV is Undervalued by 23%.
Valuation Backtest
Fagron NV
Run backtest to discover the historical profit from buying and selling FAGR stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Fagron NV
Current Assets | 335.9m |
Cash & Short-Term Investments | 137.3m |
Receivables | 84.7m |
Other Current Assets | 113.9m |
Non-Current Assets | 671.1m |
Long-Term Investments | 6.7m |
PP&E | 147.9m |
Intangibles | 482.9m |
Other Non-Current Assets | 33.5m |
Current Liabilities | 175.3m |
Accounts Payable | 104.9m |
Accrued Liabilities | 33.9m |
Other Current Liabilities | 36.5m |
Non-Current Liabilities | 367.9m |
Long-Term Debt | 357.1m |
Other Non-Current Liabilities | 10.9m |
Earnings Waterfall
Fagron NV
Revenue
|
763m
EUR
|
Cost of Revenue
|
-430.4m
EUR
|
Gross Profit
|
332.6m
EUR
|
Operating Expenses
|
-221.5m
EUR
|
Operating Income
|
111.1m
EUR
|
Other Expenses
|
-40.5m
EUR
|
Net Income
|
70.5m
EUR
|
Free Cash Flow Analysis
Fagron NV
FAGR Profitability Score
Profitability Due Diligence
Fagron NV's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Score
Fagron NV's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
FAGR Solvency Score
Solvency Due Diligence
Fagron NV's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Score
Fagron NV's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
FAGR Price Targets Summary
Fagron NV
According to Wall Street analysts, the average 1-year price target for FAGR is 21.51 EUR with a low forecast of 18.33 EUR and a high forecast of 25.2 EUR.
Shareholder Return
FAGR Price
Fagron NV
Average Annual Return | -5.24% |
Standard Deviation of Annual Returns | 13.75% |
Max Drawdown | -51% |
Market Capitalization | 1.4B EUR |
Shares Outstanding | 73 125 273 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Fagron NV engages in the development, marketing, and distribution of healthcare products and services. The company is headquartered in Nazareth, Oost-Vlaanderen and currently employs 3,061 full-time employees. The company went IPO on 2007-10-05. The company operates as a research and development (R&D) scientific pharmaceutical compounding supplier and operates through four segments: The Fagron Specialty Pharma Services segment comprises personalized medication that is produced in the Company's compounding facilities; the Fagron Trademarks segment encompasses concepts and formulations developed by the Company's research and development (R&D) team; Fagron Essentials comprises pharmaceutical raw materials, equipment and supplies for pharmacies, and the HL Technology segment includes the development and production of precision components and orthopedic tools for dental and medical professionals.
Contact
IPO
Employees
Officers
The intrinsic value of one FAGR stock under the Base Case scenario is 24.44 EUR.
Compared to the current market price of 18.76 EUR, Fagron NV is Undervalued by 23%.